MBX Biosciences (MBX) Cash from Investing Activities (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Cash from Investing Activities data on file, last reported at -$97.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 3109.83% year-over-year to -$97.1 million; the trailing twelve-month figure through Mar 2026 stood at -$184.0 million (down 6.5% YoY), and the FY2025 full-year result was -$83.7 million, up 47.88% from the prior year.
• Cash from Investing Activities grew to -$97.1 million in Q1 2026, from -$130.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $26.0 million in Q2 2025 to a low of -$130.0 million in Q4 2025.
• A 4-year average of -$37.0 million and a median of -$18.4 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 429.31% in 2025 and tumbled 3109.83% in 2026, its largest moves.
• Tracing MBX's Cash from Investing Activities over 4 years: stood at -$29.0 million in 2023, then slumped by 132.59% to -$67.3 million in 2024, then tumbled by 93.0% to -$130.0 million in 2025, then grew by 25.29% to -$97.1 million in 2026.
• Business Quant data shows MBX's Cash from Investing Activities at -$97.1 million in Q1 2026, -$130.0 million in Q4 2025, and $17.1 million in Q3 2025.